Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Genitourinary 1

Conditions

Urinary Bladder Neoplasms 3Carcinoma, Transitional Cell 3Neoplasms 2Head and Neck Neoplasms 2Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma of Lung 1Acrocephalosyndactylia 1

Interventions

pembrolizumab 3tislelizumab 1spartalizumab 1milademetan 1enzalutamide 1devimistat 1dehydroftorafur 1Tablets 1Specimen Handling 1Solutions 1Rogaratinib 1Pemetrexed 1Midazolam 1Magnetic Resonance Spectroscopy 1Letrozole 1IFL protocol 1Hydroxychloroquine 1Gemcitabine 1Fulvestrant 1Fluorouracil 1Cetuximab 1Carboplatin 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adenocarcinoma of Lung × Rogaratinib × Genitourinary × Clear all
NCT01976741 2021-05-06

Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)

Bayer

Phase 1 Completed
168 enrolled 59 charts
GenitourinaryHead & NeckThoracic

Adenocarcinoma of Lung, Urinary Bladder Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡